| Host |
Mouse |
| Klon |
Bu20a |
| Format |
Purified |
| Methode |
F, P, FL |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Bromodeoxyuridine conjugated to BSA |
Bromodeoxyuridine (BrdU)
|
Zytomed Systems GmbH |
Bu20a |
200 µg |
Purified |
RUO |
602-0135 |
-
|
| Host |
Mouse |
| Klon |
Bu20a |
| Format |
Purified |
| Methode |
F, P, FL |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
Bromodeoxyuridine conjugated to BSA |
Bromodeoxyuridine (BrdU)
|
Zytomed Systems GmbH |
Bu20a |
20 µg |
Purified |
RUO |
602-0180 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
P,F |
| Verdünnung |
1:20 - 1:40 |
| Isotyp |
Rabbit Ig |
C1q-FITC
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
F010 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
P,F |
| Verdünnung |
1:20 - 1:40 |
| Isotyp |
Rabbit Ig |
C1q-FITC
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
F010-01 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
P,F |
| Verdünnung |
1:75 - 1:100 |
| Isotyp |
Rabbit Ig |
C3c-FITC
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
F003 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
P,F |
| Verdünnung |
1:75 - 1:100 |
| Isotyp |
Rabbit Ig |
C3c-FITC
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
F003-01 |
-
|
| Host |
Mouse |
| Klon |
ZM369 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Acute rejected kidney transplant |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b/κ |
| Verdünnung |
Recombinant full-length human Complement C3 protein |
| Lokalisation |
Membrane or Cytoplasm |
C3d
|
Zeta Corporation |
ZM369 |
1 ml |
Concentrate |
CE/IVD |
Z2660ML |
-
|
| Host |
Mouse |
| Klon |
ZM369 |
| Format |
ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Acute rejected kidney transplant |
| Verdünnung |
--- |
| Isotyp |
IgG2b/κ |
| Verdünnung |
Recombinant full-length human Complement C3 protein |
| Lokalisation |
Membrane or Cytoplasm |
C3d
|
Zeta Corporation |
ZM369 |
7 ml |
ready-to-use |
CE/IVD |
Z2660MP |
-
|
| Host |
Mouse |
| Klon |
ZM369 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Acute rejected kidney transplant |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b/κ |
| Verdünnung |
Recombinant full-length human Complement C3 protein |
| Lokalisation |
Membrane or Cytoplasm |
C3d
|
Zeta Corporation |
ZM369 |
0.5 ml |
Concentrate |
CE/IVD |
Z2660MS |
-
|
| Host |
Mouse |
| Klon |
ZM369 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Acute rejected kidney transplant |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG2b/κ |
| Verdünnung |
Recombinant full-length human Complement C3 protein |
| Lokalisation |
Membrane or Cytoplasm |
C3d
|
Zeta Corporation |
ZM369 |
0.1 ml |
Concentrate |
CE/IVD |
Z2660MT |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
P,F |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit Ig |
C4c-FITC
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
F005 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
P,F |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Rabbit Ig |
C4c-FITC
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
F005-01 |
-
|
| Host |
Rabbit |
| Klon |
polyclonal |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Verdünnung |
1:50 |
| Isotyp |
Rabbit Ig |
| Verdünnung |
Synthetic peptide specific for human complement C4d conjugated to KLH (keyhole limpet hemocyanin) |
C4d
|
Zytomed Systems GmbH |
polyclonal |
250 µl |
Concentrate |
RUO |
A12-5000 |
-
|
| Host |
Mouse |
| Klon |
ZM78 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Acute rejected kidney transplant. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant full-length human complement 4d protein |
| Lokalisation |
Membrane or Cytoplasm |
C4d (Complement factor)
|
Zeta Corporation |
ZM78 |
1 ml |
Concentrate |
CE/IVD |
Z2388ML |
-
|
| Host |
Mouse |
| Klon |
ZM78 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Acute rejected kidney transplant. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant full-length human complement 4d protein |
| Lokalisation |
Membrane or Cytoplasm |
C4d (Complement factor)
|
Zeta Corporation |
ZM78 |
7 ml |
Ready-to-use |
CE/IVD |
Z2388MP |
-
|
| Host |
Mouse |
| Klon |
ZM78 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Acute rejected kidney transplant. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant full-length human complement 4d protein |
| Lokalisation |
Membrane or Cytoplasm |
C4d (Complement factor)
|
Zeta Corporation |
ZM78 |
0.5 ml |
Concentrate |
CE/IVD |
Z2388MS |
-
|
| Host |
Mouse |
| Klon |
ZM78 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Acute rejected kidney transplant. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Recombinant full-length human complement 4d protein |
| Lokalisation |
Membrane or Cytoplasm |
C4d (Complement factor)
|
Zeta Corporation |
ZM78 |
0.1 ml |
Concentrate |
CE/IVD |
Z2388MT |
-
|
| Host |
Mouse |
| Klon |
C4D204 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
rejected kidney |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
A recombinant fragment specific to Complement 4d |
| Lokalisation |
Cell membrane, Cytoplasm |
C4d Komplementfaktor
|
Diagnostic Biosystems |
C4D204 |
1 ml |
Concentrate |
CE/IVD |
MOB471 |
-
|
| Host |
Mouse |
| Klon |
C4D204 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
rejected kidney |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
A recombinant fragment specific to Complement 4d |
| Lokalisation |
Cell membrane, Cytoplasm |
C4d Komplementfaktor
|
Diagnostic Biosystems |
C4D204 |
0.1 ml |
Concentrate |
CE/IVD |
MOB471-01 |
-
|
| Host |
Mouse |
| Klon |
C4D204 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
rejected kidney |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
A recombinant fragment specific to Complement 4d |
| Lokalisation |
Cell membrane, Cytoplasm |
C4d Komplementfaktor
|
Diagnostic Biosystems |
C4D204 |
0.5 ml |
Concentrate |
CE/IVD |
MOB471-05 |
-
|
| Host |
Mouse |
| Klon |
C4D204 |
| Format |
re |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
rejected kidney |
| Verdünnung |
--- |
| Isotyp |
Mouse IgG1 |
| Verdünnung |
A recombinant fragment specific to Complement 4d |
| Lokalisation |
Cell membrane, Cytoplasm |
C4d Komplementfaktor
|
Diagnostic Biosystems |
C4D204 |
6 ml |
re |
CE/IVD |
PDM184 |
-
|
| Host |
Mouse |
| Klon |
DBMM1 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Breast carcinoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 kappa |
| Lokalisation |
Cytoplasm, cell membrane |
CA 15-3
|
Diagnostic Biosystems |
DBMM1 |
1 ml |
Concentrate |
CE/IVD |
MOB549 |
-
|
| Host |
Mouse |
| Klon |
DBMM1 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Breast carcinoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 kappa |
| Lokalisation |
Cytoplasm, cell membrane |
CA 15-3
|
Diagnostic Biosystems |
DBMM1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB549-01 |
-
|
| Host |
Mouse |
| Klon |
DBMM1 |
| Format |
Concentrate |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Breast carcinoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
IgG1 kappa |
| Lokalisation |
Cytoplasm, cell membrane |
CA 15-3
|
Diagnostic Biosystems |
DBMM1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB549-05 |
-
|
| Host |
Mouse |
| Klon |
DBMM1 |
| Format |
Ready-to-use |
| Methode |
P |
| Vorbehandlung |
EDTA |
| Positivkontrolle |
Breast carcinoma |
| Verdünnung |
- |
| Isotyp |
IgG1 kappa |
| Lokalisation |
Cytoplasm, cell membrane |
CA 15-3
|
Diagnostic Biosystems |
DBMM1 |
6 ml |
Ready-to-use |
CE/IVD |
PDM549 |
-
|
| Host |
Mouse |
| Klon |
C241:5:1:4 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Colon Carcinoma |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
CA 19-9 Antigen (Colon)
|
Diagnostic Biosystems |
C241:5:1:4 |
1 ml |
Concentrate |
CE/IVD |
MOB109 |
-
|
| Host |
Mouse |
| Klon |
C241:5:1:4 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Colon Carcinoma |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
CA 19-9 Antigen (Colon)
|
Diagnostic Biosystems |
C241:5:1:4 |
0.1 ml |
Concentrate |
CE/IVD |
MOB109-01 |
-
|
| Host |
Mouse |
| Klon |
C241:5:1:4 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Colon Carcinoma |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
CA 19-9 Antigen (Colon)
|
Diagnostic Biosystems |
C241:5:1:4 |
0.5 ml |
Concentrate |
CE/IVD |
MOB109-05 |
-
|
| Host |
Mouse |
| Klon |
C241:5:1:4 |
| Format |
ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Colon Carcinoma |
| Verdünnung |
--- |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasm |
CA 19-9 Antigen (Colon)
|
Diagnostic Biosystems |
C241:5:1:4 |
6 ml |
ready-to-use |
CE/IVD |
PDM567 |
-
|
| Host |
Mouse |
| Klon |
B72.3 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasmic, Cell Surface |
CA 72.4 Antigen (TAG-72, BRST3)
|
Diagnostic Biosystems |
B72.3 |
1 ml |
Concentrate |
CE/IVD |
MOB288 |
-
|
| Host |
Mouse |
| Klon |
B72.3 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasmic, Cell Surface |
CA 72.4 Antigen (TAG-72, BRST3)
|
Diagnostic Biosystems |
B72.3 |
0.1 ml |
Concentrate |
CE/IVD |
MOB288-01 |
-
|
| Host |
Mouse |
| Klon |
B72.3 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
1:50 - 1:100 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasmic, Cell Surface |
CA 72.4 Antigen (TAG-72, BRST3)
|
Diagnostic Biosystems |
B72.3 |
0.5 ml |
Concentrate |
CE/IVD |
MOB288-05 |
-
|
| Host |
Mouse |
| Klon |
B72.3 |
| Format |
Ready-to-use |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Breast Carcinoma |
| Verdünnung |
- |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cytoplasmic, Cell Surface |
CA 72.4 Antigen (TAG-72, BRST3)
|
Diagnostic Biosystems |
B72.3 |
6 ml |
Ready-to-use |
CE/IVD |
PDM100 |
-
|
| Host |
Mouse |
| Klon |
Ov185:1 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Ovary Carcinoma, AdenoCarcinoma |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Extracellular Membrane |
CA 125 Antigen (Ovary)
|
Diagnostic Biosystems |
Ov185:1 |
1 ml |
Concentrate |
CE/IVD |
MOB110 |
-
|
| Host |
Mouse |
| Klon |
Ov185:1 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Ovary Carcinoma, AdenoCarcinoma |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Extracellular Membrane |
CA 125 Antigen (Ovary)
|
Diagnostic Biosystems |
Ov185:1 |
0.1 ml |
Concentrate |
CE/IVD |
MOB110-01 |
-
|
| Host |
Mouse |
| Klon |
Ov185:1 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Citrate |
| Positivkontrolle |
Ovary Carcinoma, AdenoCarcinoma |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Extracellular Membrane |
CA 125 Antigen (Ovary)
|
Diagnostic Biosystems |
Ov185:1 |
0.5 ml |
Concentrate |
CE/IVD |
MOB110-05 |
-
|
| Host |
Mouse |
| Klon |
ZM53 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Ovarian carcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Full length native CA125 protein purified from human ovarian carcinoma |
| Lokalisation |
Extracellular membrane-associated. |
CA 125/ MUC16
|
Zeta Corporation |
ZM53 |
1 ml |
Concentrate |
CE/IVD |
Z2363ML |
-
|
| Host |
Mouse |
| Klon |
ZM53 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Ovarian carcinoma. |
| Verdünnung |
- |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Full length native CA125 protein purified from human ovarian carcinoma |
| Lokalisation |
Extracellular membrane-associated. |
CA 125/ MUC16
|
Zeta Corporation |
ZM53 |
7 ml |
Ready-to-use |
CE/IVD |
Z2363MP |
-
|
| Host |
Mouse |
| Klon |
ZM53 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Ovarian carcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Full length native CA125 protein purified from human ovarian carcinoma |
| Lokalisation |
Extracellular membrane-associated. |
CA 125/ MUC16
|
Zeta Corporation |
ZM53 |
0.5 ml |
Concentrate |
CE/IVD |
Z2363MS |
-
|
| Host |
Mouse |
| Klon |
ZM53 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Vorbehandlung |
Citrate or EDTA |
| Positivkontrolle |
Ovarian carcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG1 /κ |
| Verdünnung |
Full length native CA125 protein purified from human ovarian carcinoma |
| Lokalisation |
Extracellular membrane-associated. |
CA 125/ MUC16
|
Zeta Corporation |
ZM53 |
0.1 ml |
Concentrate |
CE/IVD |
Z2363MT |
-
|
| Host |
Rabbit |
| Klon |
ZR367 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Normal renal tissue |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant human CA9 protein fragment (around aa 314-410) (exact sequence is proprietary) |
| Lokalisation |
Cell surface |
CA IX
|
Zeta Corporation |
ZR367 |
1 ml |
Concentrate |
CE/IVD |
Z2740RL |
-
|
| Host |
Rabbit |
| Klon |
ZR367 |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Normal renal tissue |
| Verdünnung |
- |
| Isotyp |
IgG |
| Verdünnung |
Recombinant human CA9 protein fragment (around aa 314-410) (exact sequence is proprietary) |
| Lokalisation |
Cell surface |
CA IX
|
Zeta Corporation |
ZR367 |
7 ml |
Ready-to-use |
CE/IVD |
Z2740RP |
-
|
| Host |
Rabbit |
| Klon |
ZR367 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Normal renal tissue |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant human CA9 protein fragment (around aa 314-410) (exact sequence is proprietary) |
| Lokalisation |
Cell surface |
CA IX
|
Zeta Corporation |
ZR367 |
0.5 ml |
Concentrate |
CE/IVD |
Z2740RS |
-
|
| Host |
Rabbit |
| Klon |
ZR367 |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Normal renal tissue |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgG |
| Verdünnung |
Recombinant human CA9 protein fragment (around aa 314-410) (exact sequence is proprietary) |
| Lokalisation |
Cell surface |
CA IX
|
Zeta Corporation |
ZR367 |
0.1 ml |
Concentrate |
CE/IVD |
Z2740RT |
-
|
| Host |
Mouse |
| Klon |
121SLE |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon carcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgM |
| Verdünnung |
Precipitin lines obtained after immuno-diffusion using MAb 116-NS-19-9 and mucins isolated from an ovarian cyst of a Lewis A+B-patient (0Le) |
| Lokalisation |
Cytoplasm |
CA19-9
|
Zeta Corporation |
121SLE |
1.0 ml |
Concentrate |
CE/IVD |
Z2072ML |
-
|
| Host |
Mouse |
| Klon |
121SLE |
| Format |
Ready-to-use |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon carcinoma. |
| Verdünnung |
- |
| Isotyp |
IgM |
| Verdünnung |
Precipitin lines obtained after immuno-diffusion using MAb 116-NS-19-9 and mucins isolated from an ovarian cyst of a Lewis A+B-patient (0Le) |
| Lokalisation |
Cytoplasm |
CA19-9
|
Zeta Corporation |
121SLE |
7 ml |
Ready-to-use |
CE/IVD |
Z2072MP |
-
|
| Host |
Mouse |
| Klon |
121SLE |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon carcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgM |
| Verdünnung |
Precipitin lines obtained after immuno-diffusion using MAb 116-NS-19-9 and mucins isolated from an ovarian cyst of a Lewis A+B-patient (0Le) |
| Lokalisation |
Cytoplasm |
CA19-9
|
Zeta Corporation |
121SLE |
0.5 ml |
Concentrate |
CE/IVD |
Z2072MS |
-
|
| Host |
Mouse |
| Klon |
121SLE |
| Format |
Concentrate |
| Reaktivität |
- |
| Methode |
P |
| Positivkontrolle |
Colon carcinoma. |
| Verdünnung |
1:100 - 1:200 |
| Isotyp |
IgM |
| Verdünnung |
Precipitin lines obtained after immuno-diffusion using MAb 116-NS-19-9 and mucins isolated from an ovarian cyst of a Lewis A+B-patient (0Le) |
| Lokalisation |
Cytoplasm |
CA19-9
|
Zeta Corporation |
121SLE |
0.1 ml |
Concentrate |
CE/IVD |
Z2072MT |
-
|
| Host |
Mouse |
| Klon |
CH-19 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Pepsin |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cell Membrane |
Cadherin (Pan)
|
Diagnostic Biosystems |
CH-19 |
1 ml |
Concentrate |
CE/IVD |
MOB228 |
-
|
| Host |
Mouse |
| Klon |
CH-19 |
| Format |
Concentrate |
| Methode |
F, P |
| Vorbehandlung |
Pepsin |
| Positivkontrolle |
Tonsil |
| Verdünnung |
1:25 - 1:50 |
| Isotyp |
Mouse IgG1 |
| Lokalisation |
Cell Membrane |
Cadherin (Pan)
|
Diagnostic Biosystems |
CH-19 |
0.1 ml |
Concentrate |
CE/IVD |
MOB228-01 |
-
|